Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Paracetamol + pregabalin is a fixed-dose combination of two pharmaceutical agents used primarily for pain management, especially in settings where multimodal analgesia is desired. Paracetamol (also known as acetaminophen) acts centrally to inhibit prostaglandin synthesis, providing antipyretic and mild-to-moderate analgesic effects. Pregabalin is an anticonvulsant and neuropathic pain agent that binds to the α2δ subunit of voltage-gated calcium channels in the central nervous system, reducing neurotransmitter release and thereby decreasing neuronal excitability. The combination leverages both drugs' mechanisms to provide enhanced analgesia compared to either agent alone, particularly for postoperative or neuropathic pain[9][2]. This combination does not have a unique brand name widely recognized internationally but may be compounded or co-prescribed.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paracetamol + pregabalin.